Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACtiVe trial of autologous dendritic cells loaded with allogeneic tumor lysate in resected pancreatic cancer
NL-OMON45421Phase 2Withdrawn
- Sponsor
- Stichting Leveronderzoek
- Start
- Jun 2017
- Modality
- Small Molecules, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of MesoPher and gemcitabine in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Stichting Leveronderzoek. Primary endpoints: Feasibility of treatment procedure and Immune response against mesothelin. Planned start Jun 2017; status: withdrawn.
02
Drugs
MesoPhergemcitabine
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON45421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45421.